Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel or Doxorubicin Administered Every 21 Days in Women With Advanced Endometrial Cancer Who Have Previously Been Treated With Chemotherapy.

Next Previous
Trial Profile

A Phase III, Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel or Doxorubicin Administered Every 21 Days in Women With Advanced Endometrial Cancer Who Have Previously Been Treated With Chemotherapy.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 20 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ixabepilone (Primary) ; Doxorubicin; Paclitaxel
  • Indications Endometrial cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms IXAMPLE2
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 16 Dec 2021 This trial has been completed in France, according to European Clinical Trials Database record.
  • 19 Jul 2019 As per European Clinical Trials Database record, trial is completed in UK (24 Feb 2014).
  • 04 Mar 2015 Status changed from completed to discontinued, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top